Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma - Concepedia

Concepedia

Publication | Open Access

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

DOI Full Paper Access

202

Citations

12

References

2012

Year

Andrzej Jakubowiak, Don M. Benson, William Bensinger, David S. Siegel, Todd M. Zimmerman, Ann Mohrbacher, Paul G. Richardson, Daniel Afar, Anil Singhal, Kenneth C. Anderson

Journal of Clinical Oncology

Abstract

The combination of elotuzumab and bortezomib was generally well-tolerated and showed encouraging activity in patients with relapsed/refractory MM.

References

	Year	Citations

Page 1